Decibel Therapeutics, which is developing preclinical gene therapies for hearing loss and balance disorders, raised $127 million by offering 7.1 million shares at $18, the high end of the range of $16 to $18. The company had originally filed to sell 5.9 million shares. Decibel Therapeutics plans to list on the Nasdaq under the symbol DBTX. Citi, SVB Leerink, BMO Capital Markets and Barclays acted as lead managers on the deal.
